(SHOT) Safety Shot - Ratings and Ratios

Safety Shot, Inc. (NASDAQ:SHOT) operates at the intersection of wellness and functional beverages, specializing in the research, development, and commercialization of over-the-counter (OTC) products and intellectual property. The company’s flagship product, Safety Shot Beverage, is a scientifically formulated drink designed to lower blood alcohol content, targeting social drinkers and establishments seeking to promote responsible alcohol consumption. Beyond beverages, the company has a diversified pipeline addressing unmet needs in dermatology and personal care. Photocil is under development for treating psoriasis and vitiligo, leveraging light-activated technology. JW-700 aims to address hair loss through a topical solution, while JW-500 focuses on women’s sexual wellness. NoStingz represents an innovative approach to jellyfish sting prevention with a sunscreen product. The company distributes its offerings through a multi-channel network, including distributors, retailers, and direct-to-consumer e-commerce platforms. Formerly known as Jupiter Wellness, Inc., the company rebranded as Safety Shot, Inc. in September 2023 to align with its expanded product portfolio and strategic direction. Incorporated in 2018 and headquartered in Jupiter, Florida, Safety Shot, Inc. is positioned to capitalize on growing demand for functional health products and innovative consumer solutions.

Over the next three months, Safety Shot, Inc. is expected to focus on scaling its distribution network and advancing its R&D pipeline. The company may face short-term volatility due to its current stock price trading below its 200-day SMA of $0.92, with the 20-day SMA at $0.48 indicating near-term downward pressure. The average trading volume of 785,253 shares suggests moderate liquidity. With a market capitalization of $34.06M and a price-to-sales ratio of 52.19, the stock reflects high expectations for future growth despite current profitability challenges. The company’s pipeline, including Photocil and JW-700, could serve as catalysts for investor sentiment. However, the lack of profitability and high price-to-book ratio of 5.48 may raise concerns among value investors. Technically, the stock’s ATR of $0.06 indicates low volatility, suggesting price movements will likely remain contained in the near term. Fundamental focus will remain on execution, revenue growth, and progress in its clinical and commercial initiatives.